Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefiderocol versus colistin for carbapenem-resistant Gram-negative infections
ChiCTR2400094663Phase 3Recruiting
- Sponsor
- Huashan Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cefiderocol, colistimethate sodium and meropenem in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Healthcare-associated pneumonia (HCAP) and 4 more (2 arms), sponsored by Huashan Hospital. Primary endpoints: Clinical outcome at test of cure, Microbiological eradication at test of cure and 2 more. Started Dec 2024; status: recruiting.
02
Drugs
cefiderocolcolistimethate sodiummeropenem
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Healthcare-associated pneumonia (HCAP)Intra-abdominal infection (IAI)complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on ChiCTR2400094663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094663.